reversine

Reversine is a synthetic small molecule purine derivative first synthesized in 2004 by the group of Peter G. Schultz. It functions as a potent inhibitor of several kinases, most notably Aurora kinases (A/B/C), Mps1 (monopolar spindle 1 kinase), and MEK1, and also acts as an antagonist at the adenosine A3 receptor. Reversine is widely used in research to study chromosome segregation and cell cycle regulation due to its ability to induce cell dedifferentiation and apoptosis, particularly in cancer cells. It has shown efficacy in preclinical models for inhibiting growth of various cancer cells through mechanisms such as G2/M phase arrest and mitochondria-independent apoptosis[1][3][4]. Reversine is not approved for clinical use but serves as a lead compound for potential antitumor agents.

Other names

2-(4-morpholinoanilino)-6-cyclohexylaminopurine